Background Prior studies evaluating the relationship between tumor necrosis factor–alpha
inhibitors (TNFI) and infection were conducted in adults and had conflicting findings. We …

Background & Aims Many physicians hesitate to recommend anti–tumor necrosis factor
(TNF) therapy for pediatric patients with inflammatory bowel disease (IBD) because of …

Background Population-based studies examining the prevalence of anti–tumor necrosis
factor (anti-TNF) antagonist utilization in children and young adults with inflammatory bowel …

Background Studies have shown an association between use of tumour necrosis factor-α
(TNFα) inhibitors and increased risk of serious infection in adult inflammatory bowel disease …

Children and adolescents with inflammatory bowel disease (IBD) receiving therapy with
tumor necrosis factor α inhibitors (anti-TNFα) pose a unique challenge to health care …

Background Early initiation of tumor necrosis factor-alpha inhibitor (TNFI) therapy for
children and young adults with inflammatory bowel disease (IBD) is not well described …

Introduction: Tumor necrosis factor-α (TNF-α)-blocking agents are drugs approved for the
treatment of inflammatory bowel diseases (IBDs). Infliximab and adalimumab are approved …

Background Anti–tumor necrosis factor alpha (TNFα) therapy is effective in pediatric patients
with inflammatory bowel disease (IBD) but associated with a risk of developing anti-drug …

Background Utilization trends and health effects of infliximab and adalimumab in
inflammatory bowel disease (IBD) are incompletely understood. We aimed to describe …

Background Reports on the feasibility and effectiveness of translating proactive, antitumor
necrosis factor (TNF) therapeutic drug monitoring (TDM) for inflammatory bowel disease into …